211 related articles for article (PubMed ID: 11485353)
1. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
Guinn BA; Bertram EM; DeBenedette MA; Berinstein NL; Watts TH
Cell Immunol; 2001 May; 210(1):56-65. PubMed ID: 11485353
[TBL] [Abstract][Full Text] [Related]
2. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
3. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
[TBL] [Abstract][Full Text] [Related]
4. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
[TBL] [Abstract][Full Text] [Related]
5. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
[TBL] [Abstract][Full Text] [Related]
6. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.
Chu NR; DeBenedette MA; Stiernholm BJ; Barber BH; Watts TH
J Immunol; 1997 Apr; 158(7):3081-9. PubMed ID: 9120260
[TBL] [Abstract][Full Text] [Related]
7. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
DeBenedette MA; Shahinian A; Mak TW; Watts TH
J Immunol; 1997 Jan; 158(2):551-9. PubMed ID: 8992967
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
10. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
[TBL] [Abstract][Full Text] [Related]
12. Triggering of murine NK cells by CD40 and CD86 (B7-2).
Martín-Fontecha A; Assarsson E; Carbone E; Kärre K; Ljunggren HG
J Immunol; 1999 May; 162(10):5910-6. PubMed ID: 10229827
[TBL] [Abstract][Full Text] [Related]
13. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
Yoshida H; Katayose Y; Unno M; Suzuki M; Kodama H; Takemura S; Asano R; Hayashi H; Yamamoto K; Matsuno S; Kudo T
Cancer Immunol Immunother; 2003 Feb; 52(2):97-106. PubMed ID: 12594573
[TBL] [Abstract][Full Text] [Related]
14. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
15. CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors.
Wen T; Kono K; Shahinian A; Kiessling R; Mak TW; Klein G
Eur J Immunol; 1997 Aug; 27(8):1988-93. PubMed ID: 9295036
[TBL] [Abstract][Full Text] [Related]
16. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
17. Requirements for CD28-dependent T cell-mediated cytotoxicity.
Azuma M; Cayabyab M; Phillips JH; Lanier LL
J Immunol; 1993 Mar; 150(6):2091-101. PubMed ID: 8383716
[TBL] [Abstract][Full Text] [Related]
18. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
19. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous expression of allogenic class II MHC and B7.1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity.
Jang YJ; Nam SY; Kim MS; Seong RH; Park YS; Chung YH; Chung HY
Mol Cells; 2002 Feb; 13(1):130-6. PubMed ID: 11911464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
